113 Results

FDA grants accelerated approval for Bavencio (avelumab)to treat Merkel cell carcinoma .-Merck KgAA + Pfizer

 Added 1 day ago

Merck and Pfizer Inc. announced that the FDA has approved Bavencio (avelumab) Injection 20 mg/mL, for intravenous use, for the...

Successful Phase III trial of Ameluz (5-aminolevulinic acid) with photodynamic therapy to treat actinic keratosis.- Biofrontera AG

 Added 3 days ago

Biofrontera AG announced detailed results from its Phase III clinical trial evaluating the safety and efficacy of its topical prescription...

New data from Novartis suggests that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance.

 Added 4 days ago

Novartis has announced new data suggesting, for the first time, that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis...

Array BioPharma Inc.,withdraws from the FDA, binimetinib monotherapy for the treatment of NRAS-mutant melanoma.

 Added 5 days ago

Array BioPharma Inc. announced that it has withdrawn from the FDA Division of Oncology Products its new drug application (NDA)...

Janssen reports VOYAGE 2 and NAVIGATE Phase III studies of guselkumab (CNTO 1959) for treatment of moderate to severe psoriasis.

 Added 10 days ago

Janssen Research & Development, LLC (Janssen) announced new findings from two pivotal Phase III studies reporting the efficacy and safety...

Successful Phase III IXORA-S study finds Taltz (ixekizumab) superior to Stelara (ustekinumab) in treatment of Psoriasis.-Eli Lilly

 Added 12 days ago

Eli Lilly and Company has announced that patients with moderate-to-severe plaque psoriasis treated with Taltz (ixekizumab) demonstrated superior efficacy at...

European Commission approves Ledaga (chlormethine gel) to treat mycosis fungoides-type cutaneous T-cell lymphoma. -Actelion

 Added 18 days ago

Actelion Ltd announced that the European Commission has granted marketing authorization for the use of Ledaga (chlormethine gel) 160 micrograms/g...

GP 2017 (adalimumab biosimilar) in Phase III study shows equivalent efficacy to the reference medicine, Humira.- Sandoz -

 Added 19 days ago

Sandoz, presented data for its proposed biosimilar adalimumab (GP 2017). The Phase III confirmatory efficacy, safety and immunogenicity study met...

Analysis shows that moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear or almost clear skin following relapse during a treatment pause,- Novartis

 Added 19 days ago

Novartis announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear or almost clear...

Phase IV UNVEIL trial of Otezla (apremilast) shows benefits in moderate plaque psoriasis- Celgene

 Added 20 days ago

Celgene announced that results from its phase IV UNVEIL trial evaluating Otezla (apremilast), in patients with moderate plaque psoriasis with...

Load more